Arcturus Therapeutics (ARCT) vs Vanda Pharmaceuticals (VNDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Arcturus Therapeutics (ARCT) has outperformed Vanda Pharmaceuticals (VNDA) over the past year, gaining 19.0% versus a loss of 28.2%. Over five years, VNDA leads with a -79.2% price change compared with -81.3% for ARCT. Arcturus Therapeutics is the larger company by market cap ($214.7 million vs $208.3 million), about 1.0 times the size, while Vanda Pharmaceuticals is growing revenue faster (+8.7% vs -46.1%).
Arcturus Therapeutics converts more of its revenue into profit, with a net margin of -80.2% versus -102.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARCT | VNDA |
|---|---|---|
| Share price | $7.45 | $3.45 |
| Market cap | $214.73M | $208.32M |
| 1-day change | -1.97% | -6.13% |
| YTD return | +21.53% | -60.94% |
| 1-year return | +19.01% | -28.23% |
| 5-year return | -81.32% | -79.18% |
| Forward P/E | — | 17.22 |
| EPS (TTM) | $-3.10 | $-4.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $82.03M | $216.10M |
| Revenue growth (YoY) | -46.14% | +8.72% |
| Net income (latest FY) | $-65.78M | $-220.47M |
| Gross margin | — | 93.96% |
| Operating margin | -92.96% | -69.95% |
| Net margin | -80.19% | -102.02% |
| 52-week high | $17.96 | $9.94 |
| 52-week low | $5.50 | $3.42 |
| Distance from 52-week high | -58.52% | -65.34% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +218.12% | +233.82% |
| Average volume | 851.45K | 1.06M |
| Shares outstanding | 28.82M | 60.47M |
| Employees | 106 | 533 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARCT has outperformed VNDA by 47.2 percentage points over the past year.
- Arcturus Therapeutics is more profitable, keeping -80.2 cents of every revenue dollar as net income versus -102.0 cents for Vanda Pharmaceuticals.
- Vanda Pharmaceuticals grew revenue faster in its latest fiscal year (+8.72% vs -46.14%).
About Arcturus Therapeutics
ARCT stock →Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Vanda Pharmaceuticals
VNDA stock →Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees
ARCT vs VNDA FAQ
Which is bigger, Arcturus Therapeutics or Vanda Pharmaceuticals?
Arcturus Therapeutics (ARCT) is larger, with a market capitalization of $214.73M compared with $208.32M for Vanda Pharmaceuticals (VNDA).
Which stock has performed better over the past year, ARCT or VNDA?
ARCT returned +19.01% over the past 12 months, compared with -28.23% for VNDA (price return, excluding dividends). Past performance does not predict future results.
Are Arcturus Therapeutics and Vanda Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.